Abstract: An electrolyte-separating membrane includes a carrier made of a porous and permeable synthetic thermoplastic material that is larger than 0.8 mm in thickness and an active layer made of a material able to induce insertion and deinsertion reactions for selective transfer of cations through the membrane. The active layer is deposited on the carrier and is hermetic. The material of the active layer may in particular be a molybdenum cluster chalcogenide. The invention aims to provide an electrolyte-separating membrane that is able to transfer cations selectively and that may be manufactured with large dimensions. The invention also relates to a cation transfer method employing this membrane and to a process for manufacturing said membrane, in particular by selective laser sintering of a powdered polymer.

Abstract: A membrane separation process using a highly fluorinated polymer membrane that selectively permeates water of an aqueous ionic liquid solution to provide dry ionic liquid. Preferably the polymer is a polymer that includes polymerized perfluoro-2,2-dimethyl-1,3-dioxole (PDD). The process is also capable of removing small molecular compounds such as organic solvents that can be present in the solution. This membrane separation process is suitable for drying the aqueous ionic liquid byproduct from precipitating solutions of biomass dissolved in ionic liquid, and is thus instrumental to providing usable lignocellulosic products for energy consumption and other industrial uses in an environmentally benign manner.

Abstract: The present invention provides a compound represented by the formula (I): or a salt thereof; and a method of quantitatively analyzing an amino group-containing target substance, including labeling a target substance in samples by using, as a labeling compound, two or more of such compounds having a mutually different mass due to isotope labeling, to confer a mass difference to the target substance between two or more samples, and the like.

Abstract: L malate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are disclosed for decreasing the bitterness of eszopiclone dosage forms

Abstract: A method for producing carbon nanotubes having specific lengths, said method comprising: producing carbon nanotubes having at least two types of zones along their lengths, wherein each zone type has a characteristic structure that confers specific properties; and processing said carbon nanotubes to selectively attack one zone type more aggressively than another zone type.

Abstract: Cadherin-11 inhibitors, including 4-(2-phenylpyridin-3-yl)phenol, and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.

Abstract: The present invention relates to a smectic A phase liquid crystal material, which contains at least one heterocyclic compound. The smectic A phase liquid crystal material of the present invention may further contain at least one ester compound and an ionic compound. By using the smectic A phase liquid crystal material in a display device, a displayed image can be completely erased without any residual images after a long-term placement or a long-term drive, the contrast is generally higher than 10, and the drive voltage is generally 20 to 50 V.

Abstract: The present disclosure relates to a polymerization initiator and a modified conjugated diene polymer prepared using the same, and more particularly to a polymerization initiator which is a compound represented by the following formula 1, and a modified conjugated diene polymer prepared using the same: wherein R1 to R5 are each independently hydrogen or a C1-10 alkylgroup or its carbanion; n? represents the number of negative charges of the carbanion and is 1? to 5?; M is a metal; and n is equal to the number of carbanions in R1 to R5.

Abstract: Provided is a process for producing a high-purity pyridine compound from a crude pyridine compound that contains a diazine compound as an impurity, the method including a reaction step of reacting the crude pyridine compound with an aluminum hydride compound, and a distillation step of distilling the product obtained from the reaction step. The aluminum hydride compound preferably contains one or more compounds selected from lithium aluminum hydride and sodium aluminum hydride.

Abstract: Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

Abstract: The invention is directed to a phosphine compound represented by general formula (1) wherein R? and R? independently are selected from alkyl, cycloalkyl and 2-furyl radicals, or R? and R? are joined together to form with the phosphorous atom a carbon-phosphorous monocycle comprising at least 3 carbon atoms or a carbon-phosphorous bicycle; the alkyl radicals, cycloalkyl radicals, and carbon-phosphorous monocycle being unsubstituted or substituted by at least one radical selected from the group of alkyl, cycloalkyl, aryl, alkoxy, and aryloxy radicals; Cps is a partially substituted or completely substituted cyclopentadien-1-yl group, including substitutions resulting in a fused ring system, and wherein a substitution at the 1-position of the cyclopentadien-1-yl group is mandatory when the cyclopentadien-1-yl group is not part of a fused ring system or is part of an indenyl group. Also claimed is the use of these phosphines as ligands in catalytic reactions and the preparation of these phosphines.

Abstract: The present invention provides a liquid curable epoxy resin composition that has excellent storage stability and curing properties and provides a cured product having excellent properties, particularly, excellent organic solvent resistance. For that purpose, a clathrate containing a carboxylic acid compound and at least one selected from the group consisting of an imidazole compound represented by formula (I), wherein R1 to R4 each represent a hydrogen atom or the like, and 1,8-diazabicyclo[5.4.0]undecene-7 (DBU) is mixed in an epoxy resin. The liquid curable epoxy resin composition uses a liquid epoxy resin or an organic solvent.

Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.

Abstract: A catalyst system comprising a half-sandwich chromium complex, an activator support and an optional cocatalyst. A compound of formula Cp?Cr(Cl)2(Ln), where Cp? is ?5—C5H4CH2CH2CH?CH2 and Ln is pyridine, THF or diethylether. A compound of formula Cp?Cr(Cl)2(Ln), where Cp? is ?5—C5H4C(Me)2CH2CH2CH?CH2 and Ln is pyridine, THF or diethylether.

Abstract: A salt represented by the formula (I): wherein Q1 and Q2 each independently represent a fluorine atom or a C1-C6 perfluoroalkyl group, L1 represents *—CO—O-La- or *—CH2—O-Lb-, * represents a binding position to —C(Q1)(Q2)-, La and Lb independently represent a C1-C15 divalent saturated hydrocarbon group in which one or more —CH2— can be replaced by —O— or —CO—, ring W1 represents a C2-C36 nitrogen-containing heterocyclic group in which one or more —CH2— can be replaced by —O—, and Z1? represents an organic counter ion.

Abstract: A novel organic compound suitably used for a green-light-emitting device and an organic light-emitting device are provided. An organic light-emitting device and an image display apparatus containing a naphtho[2?,3?:5,6]indeno[1,2,3-cd]pyrene derivative represented by general formula (1) as a dopant: wherein in general formula (1), R1 to R16 are each independently selected from a hydrogen atom, a halogen atom, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkoxy groups, substituted or unsubstituted amino groups, substituted or unsubstituted aryl groups, and substituted or unsubstituted heterocyclic groups, and at least one of R3, R4, R9, and R10 is selected from substituted or unsubstituted aryl groups and substituted or unsubstituted heterocyclic groups.

Abstract: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs).

Abstract: The present invention generally relates to luminescent and/or optically absorbing compositions and/or precursors to those compositions, including solid films incorporating these compositions/precursors, exhibiting increased luminescent lifetimes, quantum yields, enhanced stabilities and/or amplified emissions. The present invention also relates to sensors and methods for sensing analytes through luminescent and/or optically absorbing properties of these compositions and/or precursors. Examples of analytes detectable by the invention include electrophiles, alkylating agents, thionyl halides, and phosphate ester groups including phosphoryl halides, cyanides and thioates such as those found in certain chemical warfare agents. The present invention additionally relates to devices and methods for amplifying emissions, such as those produced using the above-described compositions and/or precursors, by incorporating the composition and/or precursor within a polymer having an energy migration pathway.

Abstract: The present invention relates to a process for the preparation of compounds with (perfluoroalkyl)fluorohydrogenphosphate anion, and to compounds containing (perfluoroalkyl)fluorohydrogenphosphate anion and to the use thereof.

Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Abstract: The invention provides a catalyst composition for use in a cross-coupling reaction containing an iron or cobalt fluoride and a nitrogen-containing heterocyclic ring compound represented by General Formula (1A) or (1B), wherein R1 and R2 are same or different, and represent substituted or unsubstituted aryl group etc.; and R3 and R4 are same or different, and represent hydrogen etc., ?represents a single bond or a double bond, and X? represents a monovalent anion. The invention also provides a method for producing a cross-coupling compound by reacting an organic magnesium compound with an organic halogen compound in the presence of the catalyst composition.

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.

Abstract: The present invention relates to diionic liquid salts of dicationic or dianionic molecules, as well as solvents comprising such diionic liquids and the use of such diionic liquids as the stationary phase in a gas chromatographic column.

Abstract: A process for producing a biaryl compound, characterized by reacting an arylhydrazine compound, hydrogen peroxide and an aryl compound. When the reaction is conducted in the presence of a given metal or a compound of the metal or in the presence of a metal oxide obtained by reacting the given metal or a compound of the metal with hydrogen peroxide, then the yield of the biaryl compound is improved.

Abstract: Ionic liquids having melting points below about 100 C formed by reaction of a heterocyclic amine with about 2.8 and about 3.2 moles of anhydrous hydrogen fluoride per mole of amine nitrogen. Electrochemical devices having non-aqueous electrolytes containing the ionic liquids are also disclosed, as well as silicon oxide etching compositions containing the ionic liquids and etching methods in which silicon oxides are selectively removed by the etching compositions in the presence of aluminum.

Abstract: A catalyst system comprising a half-sandwich chromium complex, an activator support and an optional cocatalyst. A compound of formula Cp?Cr(Cl)2(Ln), where Cp? is ?5-C5H4CH2CH2CH?CH2 and Ln is pyridine, THF or diethylether. A compound of formula Cp?Cr(Cl)2(Ln), where Cp? is ?5-C5H4C(Me)2CH2CH2CH?CH2 and Ln is pyridine, THF or diethylether.

Abstract: This invention relates to a process for preparing functionalized aryl, heteroaryl, cycloalkenyl, or alkenyl compounds, by a transition-metal-catalyzed cross-coupling reaction of a substituted or unsubstituted aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide, where X is a halide, diazonium, tosylate (p-toluenesulphonate), mesylate (methanesulphonate) or triflate (trifluoromethanesulphonate) leaving group.

Abstract: Provided is a process for producing a high-purity pyridine compound from a crude pyridine compound that contains a diazine compound as an impurity, the method including a reaction step of reacting the crude pyridine compound with an aluminum hydride compound, and a distillation step of distilling the product obtained from the reaction step. The aluminum hydride compound preferably contains one or more compounds selected from lithium aluminum hydride and sodium aluminum hydride.

Abstract: Disclosed is a method for producing “a salt or a complex comprising imide and an organic base”, characterized by reacting halogenated sulfuryl or halogenated phosphoryl with ammonia in the presence of an organic base. According to this method, a target imide compound can be produced in a high yield while significantly suppressing the production of by-products. Further, by reacting the obtained imide compound with an alkali metal hydroxide or an alkaline earth metal hydroxide, an imide metal salt can be easily derived.

Abstract: An object of the invention is to provide a novel sphingosine compound with an inhibitory activity against sphingomyelinase, and a method for producing the sphingosine compound. The novel sphingosine compound or a salt thereof according to the invention is represented by Formula (1): wherein one of R1 and R2 is hydrogen, and the other is a group represented by Formula (G): wherein n is 0 or 1; and R3 is hydrogen, C1-23 alkyl, C3-8 cycloalkyl, C2-6 alkenyl, C1-6 alkoxy, C3-8 cycloalkyloxy, phenyl, or furil.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: The invention relates to a pentacyclic anion salt and to the use thereof in electrolyte compositions. The compound comprises an inorganic, organic or organometallic cation M of valency m (1?m?3) and m anions corresponding to the formula (I) in which Rf is a —CFZ?Z? group in which Z? is F or a perfluoroalkyl group having from 1 to 3 carbon atoms, and Z? is an H, F or Cl group, an optionally fluorinated or perfluorinated alkoxy group having from 1 to 5 carbon atoms, an optionally fluorinated or perfluorinated oxaalkoxy group having from 1 to 5 carbon atoms or an optionally fluorinated or perfluorinated alkyl group having from 1 to 5 carbon atoms; Z? being other than F when Z? is F. An electrolyte composition comprises said salt in solution in a liquid solvent or a polymer solvent.

Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.

Abstract: The invention relates to a polyisocyanurate comprising isocyanurate rings linked by linker groups coupled to the nitrogen atoms of said rings. The polyisocyanurate may be microporous or mesoporous or both microporous and mesoporous.

Abstract: Subject of the invention is a dehydrogenation catalyst for dehydrogenating methylpiperidine to methylpyridine. Subject of the invention are also methods for preparing the catalysts obtained thereby and methods, in which the catalysts are used.

Abstract: This invention relates to novel 4-benzhydryl-tetrahydro-pyridine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein Ra represents hydrogen or C1-6-alkyl; Rband Rc independent of each other represent a phenyl group, which phenyl group is optionally substituted with one or more substituents independently selected from the group consisting of halo, trifluoromethyl, trifluoromethoxy, cyano, C1-6-alkoxy and methylenedioxo useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Abstract: The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor.

Abstract: A compound for an organic thin film transistor having a structure shown by the following formula (1): X1-L-Ar-L-X2??(1) wherein L is —C?C—, or —CH?CH— in a trans configuration, X1 and X2 are independently a substituted or unsubstituted aromatic heterocyclic group having 5 to 60 ring atoms, and their bonding positions to L are in heterocycles, Ar is a substituted or unsubstituted aromatic hydrocarbon group having 6 to 60 ring carbon atoms, or a substituted or unsubstituted aromatic heterocyclic group having 5 to 60 ring atoms, and at least one of X1, X2 and Ar is a bi- or higher-fused ring.

Abstract: A quaternary nitrogen-containing corrosion inhibitor of formula wherein is an aromatic, nitrogen-containing ring of 5 to 14 ring atoms, optionally containing an additional N, O or S ring atom and optionally substituted with one or more alkyl, alkenyl, aryl, arylalkyl, cycloalkyl, amino, aminoalkyl, alkoxy, hydroxylalkyl, or cyano groups, or a mixture thereof; Y is a group of formula —OC(O)R1 or —C(O)R1; L is C1-C10 alkyl, C2-C10 alkenyl or a group of formula —CH2CH(OR2)CH2—; R1 is C8-C20 alkyl or C8-C20 alkenyl; R2 is H or —C(O)R1; R3 and R4 are independently selected from H, alkyl, alkenyl, amino, alkoxy, hydroxylalkyl and cyano; and X is Br, Cl or I is particularly useful for inhibiting corrosion in oil and gas field applications.

Abstract: A method for producing a compound having a deuterated aromatic ring or heterocyclic ring according to the invention includes heating a compound having an aromatic ring or heterocyclic ring in the presence of heavy water, a transition metal and a metal which generates deuterium. As the metal which generates deuterium, at least one metal selected from the group consisting of aluminum, magnesium, zinc, iron, lead and tin is preferred. As the transition metal, at least one metal selected from the group consisting of platinum, palladium, ruthenium and rhodium is preferred. The heating is preferably carried out by microwave irradiation.

Abstract: The carbon nanomaterials and methods relate to methods for causing carbon nanospheres to be readily dispersible in a material. The carbon nanospheres are rendered dispersible using a cationic surfactant. The surfactant includes one or more cationic group that can bond to the surface of the carbon nanospheres, without detrimentally affecting the unique properties of carbon nanospheres. The dispersible carbon nanospheres can be dried (i.e., solvent is driven off) while maintaining their dispersibility in solvents and other materials.

Abstract: A liquid crystal (LC) compound having generally required physical properties, low viscosity, proper optical anisotropy, proper dielectric anisotropy and good compatibility with other LC compounds is described. An LC composition including the compound and an LCD device including the composition are also described. The compound is expressed by formula (1a): wherein the ring A1 and the ring A2 are independently 1,4-phenylene, pyridine-2,5-diyl, pyrimidine-2,5-diyl or naphthalene-2,6-diyl, in which any hydrogen can be replaced by halogen; Z1, Z2 and Z3 are independently a single bond, —(CH2)2—, —(CH2)4—, —CH?CH—, —C?C—, —CF2O—, —OCF2—, —COO— or —OCO—; Xa, Xb, Xc, Xd, Xe and Xf are independently hydrogen or fluorine; Y is —OCH2F, —OCHF2, —OCF3, —SCH2F, —SCHF2, —SCF3, —CH2F, —CHF2, —CF3, fluorine or chlorine; La and Lb are independently hydrogen or fluorine; and “l” and “m” are independently equal to 0 or 1.

Abstract: The invention relates to 2-(pyridin-2-yl)-pyrimidine compounds of general formula (I) and their use for controlling pathogenic fungi and as plant protection products that, as an active constituent, contain compounds of this type: In general formula (I), k represents 0, 1, 2, 3; m represents 0, 1, 2, 3, 4 or 5; n represents 1, 2, 3, 4 or 5; R1, independent of one another, represents halogen, OH, CN, NO2, C1-C4 alkyl, C1-C4 alkyl halide, C1-C4 alkoxy, C1-C4 alkoxy halide, C2-C4 alkenyl, C2-C4 alkynyl, C3-C8 cycloalkyl, C1-C4 alkoxy-C1-C4 alkyl, amino, phenoxy, which is optionally substituted by halogen or C1-C4 alkyl, NHR, NR2, C(Ra)?N—ORb, S(?O)pA1 or C(?O)A2, or two radicals R1 bound to adjacent carbon atoms can, together, also represent a group —O-Alk-O—, wherein Alk represents a linear or branched C1-C4 alkylene, and 1, 2, 3 or 4 hydrogen atoms can also be replaced by halogen; R2 represents C1-C4 alkyl halide, C1-C4 alkoxy, C1-C4 alkoxy halide, hydroxy, halogen, CN or NO2; whereby R2 can also represent

Abstract: The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the general formula: where X?N or P; and Y?O or S.

Abstract: Use vaginal odorant compounds for controlling motile cell chemotaxis.

Abstract: An object of the present invention is to provide an agent for use in the effective treatment and prevention of endometriosis and uterine adenomyosis. The present invention relates to an agent for use in the treatment and prevention of endometriosis or uterine adenomyosis, comprising, as an active ingredient, a compound selected from the group consisting of 3-ethylpyridine, 3-methylpyridine, 2-ethylpyridine, and 2-methylpyridine.

Abstract: The invention provides a catalyst composition for use in a cross-coupling reaction containing an iron or cobalt fluoride and a nitrogen-containing heterocyclic ring compound represented by General Formula (1A) or (1B), wherein R1 and R2 are same or different, and represent substituted or unsubstituted aryl group etc.; and R3 and R4 are same or different, and represent hydrogen etc., represents a single bond or a double bond, and X? represents a monovalent anion. The invention also provides a method for producing a cross-coupling compound by reacting an organic magnesium compound with an organic halogen compound in the presence of the catalyst composition.

Abstract: Ionic liquids of the general formula C+A? where C+ represents an organic cation, specifically, but not limited to the imidazolium, pyridinium, isoquinolinium, ammonium types, which have aliphatic and aromatic substituents, while A? represents a carboxylate, aromatic and aliphatic anion. The ionic liquids are synthesized under conventional heating or microwave irradiation This invention is also related to the application of ionic liquids to remove sulfur compounds of naphthas through a liquid-liquid extraction and the recovery and reuse of ionic liquids by the application of heat, reduced pressure and washing with solvents.

Abstract: Provided are 5-substituted quinazolinone compounds, for example, of formula (I), and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use for treating angiogenesis or cytokine related disorders, and pharmaceutical compositions of these compounds are disclosed.

Abstract: The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).